ZNRF2 and sarcoma: TRIM22 inhibits osteosarcoma progression by promoting proteasomal degradation of zinc and ring finger 2 (ZNRF2) independent of goblet-like ECH-associated protein 1 (KEAP1), resulting in autophagic death of sarcoma cells [71].